Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Dinardo, C.; Pratz, K.; Pullarkat, V.; Jonas, B.; Arellano, M.; Becker, P.; Frankfurt, O.; Konopleva, M.; Wei, A.; Kantarjian, H.; Xu, T.; Hong, W.; Chyla, B.; Potluri, J.; Pollyea, D.; Letai, A.

doi:10.1182/blood-2018-08-868752

Public

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Shared by NobleBlocks on Jan 3, 2019 • 12:00 AM UTC

Authors:

C. Dinardo

K. Pratz

V. Pullarkat

Abstract

Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance. We report safety and efficacy of venetoclax with decitabine or azacitidine from a large, multicente...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!